Alnylam Ramps Up Commercial Planning For Givosiran Based On Phase III Data

The company expects to complete a rolling NDA submission for its second RNAi therapeutic in mid-2019, and sees an opportunity to target severe and more moderate patients with acute hepatic porphyria.